Safety and Tolerability of Implanted Subcutaneous Cardioverter-Defibrillator Systems
Open Access
- 8 September 2022
- journal article
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 18 (4), 427-432
- https://doi.org/10.20996/1819-6446-2022-08-05
Abstract
Aim. To study the safety and tolerability of the subcutaneous implantable cardioverter defibrillator (S-ICD) after implantation. Material and methods. The results of 33 patients with implanted S-ICD 6 months follow-up. The criteria for inclusion in the observational study were: age over 18 years, indications for primary or secondary prevention of sudden cardiac death. The exclusion criteria were indications for implantation of transvenous ICD (patients with sustained monomorphic ventricular tachycardia, the need for anti-bradycardia or resynchronization therapy), as well as patients with a QRS complex of more than 130 msec. All patients underwent a standard preoperative examination (routine blood tests, chest X-ray, transthoracic echocardiography), quality-of-life questionnaires and transesophageal echocardiography. At follow-up, patients were examined after 6 months after implantation, the device was interrogated and a quality-of-life questionnaire was completed. All episodes of shock therapy and complications were documented. Results. Male patients predominated (84%), with a mean age of 57 [43;62] years. Left ventricular ejection fraction was 30% [26;34]. The mean QRS duration was 100 [94;108] msec. According to the of 24-hour Holter ECG monitoring, episodes of unstable VT were recorded in 42.4% of patients. The most common indications for S-ICD implantation were dilated (33%) and ischemic cardiomyopathy (42%). Primary prevention was indicated in 97% of patients. At the end of the implantation of the S-ICD, the patients underwent a defibrillation test and device configuration. In 63.6% of cases, during automatic tuning, the device selected the primary perception vector. In 27.2% of patients, optimal recognition of the subcutaneous signal was observed in the secondary vector, and in 9.2% of patients, the alternative vector was favorable. All patients underwent two-zone programming. The conditional shock zone was programmed at an average rate of 192 beats/min (range 180-210 beats/min) and the shock zone was programmed at an average rate of 222 beats/min (range 220-240 beats/min). Perioperative complications occurred in two patients. During the follow-up period, no shocks were recorded in 27 patients. Adequate shocks for 6 months were recorded in two patients. During 6 months of observation, one lethal outcome was noted due to complications of viral pneumonia. During the observation period, there were no rehospitalizations for cardiovascular diseases. Conclusion. The use of S-ICD, even in patients with structural myocardial disease who do not require antibradycardia pacing, is effective in preventing SCD. The number of inadequate discharges and the number of complications in clinical practice is comparable to the data of multicenter studies. S-ICD implantation was not accompanied by a decrease in quality of life. Careful selection of candidates, along with state-of-the-art device programming, is an important parameter for the selection and success of S-ICD application.Keywords
This publication has 21 references indexed in Scilit:
- Infection and mortality after implantation of a subcutaneous ICD after transvenous ICD extractionHeart Rhythm, 2015
- 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac deathEuropean Heart Journal, 2015
- Safety and Efficacy of the Totally Subcutaneous Implantable DefibrillatorJournal of Invasive Cardiology, 2015
- Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD RegistryEuropean Heart Journal, 2014
- Safety and Efficacy of a Totally Subcutaneous Implantable-Cardioverter DefibrillatorJournal of the American College of Cardiology, 2013
- Reduction in Inappropriate Therapy and Mortality through ICD ProgrammingThe New England Journal of Medicine, 2012
- Rationale and design of the PRAETORIAN trial: A Prospective, RAndomizEd comparison of subcuTaneOus and tRansvenous ImplANtable cardioverter-defibrillator therapyAmerican Heart Journal, 2012
- Systematic Review of the Incidence of Sudden Cardiac Death in the United StatesJournal of Invasive Cardiology, 2011
- Prophylactic Implantation of a Defibrillator in Patients with Myocardial Infarction and Reduced Ejection FractionThe New England Journal of Medicine, 2002
- Improved Survival with an Implanted Defibrillator in Patients with Coronary Disease at High Risk for Ventricular ArrhythmiaThe New England Journal of Medicine, 1996